Mark W. Pocock

Mark W. Pocock

Auto-generated profile, based on publicly available information

Mark W. Pocock

QIMR Berghofer, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
MPMark W. Pocock
Mark W. Pocock
JRJanice D. Reid
Janice D. Reid
HRHarley R. Robinson
Harley R. Robinson
NCNatalie Charitakis
Natalie Charitakis
JKJames R. Krycer
James R. Krycer
JHJames E. Hudson
James E. Hudson
Maturation of human pluripotent stem (hPS) cell-derived cardiomyocytes is critical for their use as a model system. Here we mimic human heart maturation pathways in the setting of hPS cell-derived cardiac organoids (hCOs). Specifically, transient activation of 5′ AMP-activated protein kinase and estrogen-related receptor enhanced cardiomyocyte maturation, inducing expression of mature sarcomeric and oxidative phosphorylation proteins, and increasing metabolic capacity. hCOs generated using the directed maturation protocol (DM-hCOs) recapitulate cardiac drug responses and, when derived from calsequestrin 2 (CASQ2) and ryanodine receptor 2 (RYR2) mutant hPS cells exhibit a pro-arrhythmia phenotype. These DM-hCOs also comprise multiple cell types, which we characterize and benchmark to the human heart. Modeling of cardiomyopathy caused by a desmoplakin (DSP) mutation resulted in fibrosis and cardiac dysfunction and led to identifying the bromodomain and extra-terminal inhibitor INCB054329 as a drug mitigating the desmoplakin-related functional defect. These findings establish DM-hCOs as a versatile platform for applications in cardiac biology, disease and drug screening.

3 December 2024
Verified
Preprint
Open access
PDF file
MPMark Pocock
Mark Pocock
LDLynn Devilée
Lynn Devilée
RFRebecca Fitzsimmons
Rebecca Fitzsimmons
JHJames Hudson
James Hudson
We present a unified protocol for the genetic modification of human pluripotent stem cells with CRISPR/Cas9, and the subsequent generation of clonal lines for downstream disease modeling applications. We demonstrate two step cases for generating gene-knockouts, and for homozygous or heterozygous genetic knock-in mutations. Both step cases then converge and adopt the same single-cell cloning method. By presenting the entire procedure, from experimental design to quality control, we are able to highlight the interdependencies between the editing and cloning stages which are often overlooked. Following our protocol the user should hope to acquire high-quality clonal hPSC lines carrying their desired genetic mutation within 6-8 weeks.